Q4 Results: Small Cap Pharma Company Announces 1:5 Stock Split, Dividend

Small cap company operating in pharmaceuticals sector, Gujarat Themis Biosyn declared net profit of Rs 11.69 crore for the fourth quarter ended March, 2023 as against Rs 9.79 crore profit declared in Q4 FY22. The company also announced sub-division/stock split in the proportion of 1:5 and dividend. Shares of Gujarat Themis Biosyn gave return of 2090% return in last 5-years. Check details below:

Gujarat Themis Biosyn Q4: Gujarat Themis Biosyn's yearly net profit zoomed to Rs 57.97 crore from Rs 43.62 crore reported in the previous year. Revenue from operations soared 29.7% to Rs 148.97 crore.

Gujarat Themis Biosyn Announces Stock Split: As per the company's regulatory filing, "The Board considered the proposal for sub-division of 1 equity share of the Company having face value of Rs.5/- each into 5 (five) equity shares having face value of Rs.1/- each, subject to regulatory/statutory approvals as may be required and the approval of the shareholders of the Company for the financial year 2023-24."

Gujarat Themis Biosyn Declares Dividend: According to the BSE filing of Gujarat Themis, "Recommended dividend for Financial Year ended 31.03.2023 of Rs.1/- l.e. @ 20% per equity share having face value of Rs.5/- , aggregating to Rs. 1,45,28,702. The payment is subject to the approval of shareholders at the ensuing AGM."

Gujarat Themis Biosyn Stock Performance & Return: Last trading price of Gujarat Themis Biosyn share is Rs 804.85 apiece with intraday gain of 2.63% on BSE. Gujarat Themis share's 52-week high price is Rs 921.05 apiece and 52-week low price is Rs 376.10 apiece, respectively. The company's market capitalisation is Rs 1,169.34 crore. The shares of the company jumped 28% in last 3-months, gave return of 103% in last 1-year, 202% return in last 2-years, 322% return in last 3-years and a whopping 2090% return in last 5-years.

Gujarat Themis Biosyn About: Gujarat Themis Biosyn Limited was incorporated in 1981 as a joint sector company with GIIC Ltd. and Chemosyn (P) Ltd. It commenced production in August 1985. It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd, according to its official website.